Management of hyperuricemia in gout: focus on febuxostat by Reinders, Mattheus K & Jansen, Tim L Th A
© 2010 Reinders and Jansen, publisher and licensee Dove Medical Press Ltd. This is an Open Access 
article which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical Interventions in Aging 2010:5 7–18
Clinical Interventions in Aging

R e v I e w
Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com
Dovepress 
Management of hyperuricemia in gout: focus 
on febuxostat
Mattheus K Reinders1 
Tim L Th A Jansen2
1Clinical Pharmacy,   Atrium 
Medisch Centrum Parkstad, 




Correspondence: MK Reinders 
Atrium Medisch Centrum Parkstad; 
Henri Dunantstraat 5, 6941 PC Heerlen, 
The Netherlands 
Tel +31 45 5767419 
Fax +31 45 5767279 
email m.reinders@atriummc.nl
Abstract: Gout is the most common inflammatory arthritis in an elderly population, and can 
be diagnosed with absolute certainty by polarization microscopy. However, diagnosis may be 
challenging because atypical presentations are more common in the elderly. Management of 
hyperuricemia in the elderly with gout requires special consideration because of co-medication, 
contra-indications, and risk of adverse reactions. Urate-lowering agents include allopurinol 
and uricosuric agents. These also must be used sensibly in the elderly, especially when renal 
function impairment is present. However, if used at the lowest dose that maintains the serum 
urate level below 5.0 to 6.0 mg/dL (0.30 to 0.36 mmol/L), the excess urate in the body will 
eventually be eliminated, acute flares will no longer occur, and tophi will resolve. Febuxostat, 
a new xanthine oxidase inhibitor, is welcomed, as few alternatives for allopurinol are available. 
Its pharmacokinetics and pharmacodynamics are not significantly altered in patients with 
moderate renal function or hepatic impairment. Its antihyperuricemic efficacy at 80 to 
120 mg/day is better than “standard dosage” allopurinol (300 mg/day). Long-term safety data 
and efficacy data on tophus diminishment and reduction of gout flares have recently become 
available. Febuxostat may provide an important option in patients unable to use allopurinol, 
or refractory to allopurinol.
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Introduction
Gout is the collective name for several disorders that are characterized by the formation 
and deposition of monosodium urate (MSUr) crystals. The condition is associated with 
recurrent episodes of acute joint pain due to the deposition of MSUr crystals in the 
synovial fluid. In addition to the effects observed in the joints, skin/subcutaneous tissue 
and kidneys may also be affected by tophaceous deposits, cellulitis, urate nephropathy, 
and/or kidney stones, respectively. In most cases, no identifiable underlying cause of 
gout is present, but evident factors are usually present that may contribute to increases in 
urate (uric acid) levels, such as reduced renal function, obesity, and the use of diuretics. 
Hyperuricemia may exist for several years to decades before the first symptoms of 
gout attacks appear; therefore it is a disease associated and correlated with aging.
Gout is one of the most common inflammatory arthritis affecting the elderly; however 
in general it appears to be poorly managed.1–3 Partly this is due to an absence of sufficient 
treatment strategies and guidelines. In 2006, the European League against Rheumatism 
(EULAR) published the first international recommendations for the diagnosis and treat-
ment of gout.4,5 The development of these EULAR and British Society of Rheumatology 
(BSR) guidelines coincided with improved professional and patient education as well Clinical Interventions in Aging 2010:5 
Reinders and Jansen Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
as the urge for improved professional performance. Until 
recently, allopurinol was the only antihyperuricemic drug 
worldwide available. Two uricosurics with barriers regard-
ing availability (benzbromarone and probenecid) have been 
available for years, but their exact place in treatment strat-
egy is not clear. In 2008 and 2009 respectively, European 
Medicines Agency (EMEA) and Food and Drug Adminis-
tration (FDA) have approved febuxostat, a novel selective 
xanthine inhibitor, for the treatment of hyperuricemia in gout 
patients, respectively. Febuxostat greatly expands the treat-
ment options for refractory or allopurinol-intolerant gout, 
given the huge prevalence of the disorder and good worldwide 
availability of only one antihyperuricemic drug.
The incidence and prevalence of gout in the elderly 
is increasing.1,6,7 This appears related to improved lifes-
pan leading to similar increases in age-related diseases 
(eg, cardiovascular diseases) and their associated adverse 
effects of treatment (eg, diuretics and low-dose salicylates) 
which can increase the risk of gout. “Elderly onset gout” 
differs from “classical” gout found in middle-aged men in 
several respects: no male predominance but an equal gender 
distribution, polyarticular presentation with upper-extremity-
joint involvement, fewer acute gouty episodes, indolent 
clinical course, and an increased incidence of tophi.1,8 
Several reviews have addressed the specific challenges of 
gout treatment in the elderly.1,8–11 This review will focus on 
febuxostat for the management of gout in the elderly.
Gout pathophysiology
Uric acid is formed from nucleic acid either endogenously 
from cell breakdown or exogenously from metabolism of 
food. Cooling and acidification of the microenvironment, 
which can result in acute formation of urate crystals, reduce 
the solubility of MSUr. The gut excretes one-third of urate 
and two-thirds are excreted renally. Renal urate transport 
is typically explained by a 4-component model: glomerular 
filtration, a near-complete reabsorption of filtered urate, 
subsequent secretion, and postsecretory reabsorption in the 
remaining proximal tubule.12 Recently, several new urate 
transporters have been identified as playing key roles in 
urate homeostasis, including URAT-1, and Glut9.12,13 The 
regulation of serum uric acid levels is under a strong genetic 
control. A recent meta-analysis of genome-wide association 
scans shows that common DNA variants at 9 different 
loci are associated with uric acid concentrations.14
Excessive consumption of alcohol (particularly beer), 
sweetened soft drinks, fructose, meat, and seafood can also 
increase levels of serum urate (sUr).12
Inhibition of urate transporters can be achieved by 
uricosurics, and production of uric acid can be inhibited 
using xanthine oxidase inhibitors, such as allopurinol. 
Febuxostat is a new selective inhibitor of xanthine oxidase. 
Uric acid deposits can also be lysed by the enzyme uricase, 
the coding gene for which became defective in humans 
in the Miocene because of an evolutionary mutation. The 
combined absence of uricase and almost total reabsorption 
of filtered urate explains that humans (and the greater apes) 
have 10-fold higher sUr levels than other mammals.
Drug-induced hyperuricemia
Chronic diuretic therapy is associated with reduced excretion 
of uric acid. Mechanisms are increased uric acid reabsorp-
tion in the proximal tubule secondary to volume depletion, 
and competition between the diuretic and uric acid for the 
organic acid secretory mechanism in the proximal tubule.15 
Low-dose diuretic therapy in hypertensive patients does not 
seem to alter serum urate levels significantly.15,16 Indeed, the 
requirement for anti-gout therapy in hypertensive patients is 
doubled for thiazide doses of 25 mg/day (in hydrochloro-
thiazide equivalents); no significant increase in risk is seen 
for lower doses.15,17 Similarly, low-dose therapy with a loop 
diuretic is not associated with hyperuricemia.15,18 However, 
low-dose diuretic therapy may be effective in hypertension 
but insufficient in patients with chronic heart failure who 
often additionally suffer from chronic renal failure.
Salicylates are known to interact with renal urate 
handling and low doses inhibit urate excretion. In one study 
it was found that even mini-dose aspirin (75 mg/day) was 
associated with a 15% decrease of urate excretion in elderly 
patients.19 Thus, in elderly people with cardiovascular 
diseases not only diuretics, but also mini-dose aspirin is 
of importance.
Characteristics of gout presentation
Gout can be diagnosed with certainty only by identification 
of urate (MSUr) crystals, present in joints during acute 
attacks of gout, or in tophi. The clinical practitioner can 
confirm the presence and type of crystals by polarization 
microscopy.4,20,21
The characteristic profile of gout is that of severe 
monoarthritis occurring within several hours. The first 
metatarsophalangeal joint is affected in 50% of gout attacks, 
and this is known as podagra. Gout may be localized in 
other joints, but shoulders, hips, and the vertebral column 
are rarely affected. The initial gout attack usually involves 
monoarthritis, but long-term gout over several years may Clinical Interventions in Aging 2010:5 
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become polyarticular and could lead to increasing joint 
damage. Similarly, a positive uric acid balance over a 
number of years can cause tophaceous deposits, possibly 
with periodic arthritis.
Urate production
Primary gout tends to involve low urate excretion, which is 
primarily originated in the proximal tubule. Only a minority 
of cases involves overproduction of urate. In some treat-
ments of cancer (particularly lymphomas and leukemias), 
patients can develop tumour lysis syndrome including severe 
hyperuricemia with risk of urate nephropathy.
Urate nephropathy in gout
Aggressive chemotherapy among patients with chronic 
leukemia or malignant lymphoma could cause an excessive 
supply of uric acid resulting in acute urate nephropathy 
due to the deposition of urate crystals in collection ducts 
and ureters. Several kinds of urate crystals can be found, 
including uric acid crystals, amorphous urate, monosodium 
urate, and ammonium urate crystals.
In chronic hyperuricemia, the risk of developing renal 
crystals increases as serum urate concentrations rise. The risk 
is about 10% with serum urate 0.42 to 0.48 mmol/L, but can 
rise to 50% with serum urate concentrations 0.70 mmol/L. 
In the absence of stones or other risk factors (such as hyper-
tension), the risk of urate nephropathy has generally 
been considered low.22
Radiographic presentations of gout
X-ray examination at the initial onset of gout has revealed no 
abnormalities except for possible pre-existing arthrosis and 
soft tissue edema. Cartilage and bone might be affected by 
chronic and/or recurring arthritis, and subsequently exhibit 
narrowing of the joint cavity because of the disappearance 
of cartilage, and erosions or cysts because of contact with 
juxta-articular bone. These abnormalities and the appearance 
of the erosions may raise suspicions of gout, but erosions are 
a secondary manifestation and non-diagnostic characteristic 
of early gout. In chronic gout, however, some of these char-
acteristic changes can help with diagnosis.
Treatment strategies for gout
Several approaches to the treatment of gout are available 
depending on the patient’s presentation of the disease. Optimal 
treatment often requires a combination of pharmacological 
intervention and lifestyle changes. Treatment should be 
tailored to the patient’s prognostic factors (high sUr, previous 
attacks, and radiographic signs), the clinical phase of 
the disease (acute, recurrent, tophaceous) and general 
risk factors, such as obesity, alcohol consumption, renal 
impairment, use of diuretics or other risk factors for 
secondary hyperuricemia. Primary prevention of gout often 
involves changes in lifestyle, such as a low-purine/weight-
reducing diet or restricting alcohol intake; however, many 
patients are unlikely to undertake such changes until they 
are diagnosed with the disease, which often occurs when 
the symptoms are presented in the form of an attack of gout. 
Acute gout is usually treated by reducing the inflammation of 
the affected joint with non-steroidal anti-inflammatory drugs 
(NSAIDs), colchicine, corticosteroids, and cooling.5,23–26 
Once the acute gout has subsided the objective is to prevent 
disease recurrence. This might involve lifestyle changes and 
low doses of NSAIDs or colchicine. In patients with high 
sUr levels who suffer from frequent attacks of gout, the use 
of urate-lowering drugs is warranted.
The following is an overview of the different drug classes 
and their potential use as part of the treatment strategies for 
gout. Information on these drugs is presented in Table 1 and 
the current therapeutic strategy is summarized in Table 2.
Some drugs have a documented (modest) urate lowering 
side effect because of enhanced urate clearance by the kidney. 
These include losartan, fenofibrate, high dose aspirin and 
vitamin C.27–30 In patients with gout, these drugs might be 
preferred above other drugs in the same class.
Primary prevention of gout
Primary prevention of gout involves changes in lifestyle, 
such as changes to diet (low-purine/weight-reducing diet) and 
restricting alcohol consumption. No randomized studies have 
been conducted evaluating the effect of lifestyle changes on 
the incidence of attacks in patients with gout. Nevertheless, 
experts agree that lifestyle changes may have some effect. 
Physicians in daily practice also give lifestyle advice, when 
gout symptoms appear. However, fewer than 20% of patients 
with gout seeking medical advice are prepared to make long-
term changes in lifestyle.31 Recently, the negative role of meat, 
seafood and beer consumption, and the protective role of 
dairy products in the development of gout were demonstrated 
in a prospective study over a 12-year period among a 
population of around 47,000 healthy male subjects.32
Treatment options for prevention 
of recurrence of gout
When gout has subsided, it is important to reduce the 
sUr concentration to prevent recurrence of gouty attacks. Clinical Interventions in Aging 2010:5 10
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This involves restriction of alcohol, weight-loss in cases of 
obesity (not too rapidly as this can trigger gout), and ensuring 
adequate diuresis. Dietary measures are very important.32 
However, a strict low-purine diet can achieve only a limited 
reduction in sUr levels (0.10 mmol/L or 1.7 mg/dL), and 
many patients have difficulty with adhering to long-term 
dietary changes.31 If possible, it is recommended that patients 
should discontinue diuretics if indicated for hypertension 
(find alternative antihypertensives), but should continue 
diuretics if indicated for overhydration/congesive heart 
failure. However, the effectiveness of these measures is 
limited and is not supported by controlled studies.
With tophaceous or recurrent gout (2 attacks per annum) 
the use of urate-lowering therapy may be warranted.33 
In contrast, asymptomatic hyperuricemia does not require 
specific treatment. The maintenance dose of urate-lowering 
drugs is preferably adjusted to the clinical effect: (1) preven-
tion of gout attacks without using colchicine and/or NSAIDs, 
(2) disappearance of tophi based on the sUr-concentration 
with tophaceous deposits. Tophi may well disappear when 
lower sUr target values have been achieved to at least “normal” 
levels, but preferably low to normal (0.30 mmol/L).34 
In order to prevent further attacks of gout, stable sUr target 
values of at least 0.36 mmol/L are required, but in some 
Table 2 Suggested experience-based strategy for initiation of antihyperuricemic therapy
1.  Confirmation of diagnosis: detect urate crystals by means of polarization microscopy
2.    Two or more gout flares per annum or tophi/joint destruction due to gout attacks
3.    Therapeutic advice1: allopurinol 100–300 mg/day2 
   a.  allopurinol intolerance: consider febuxostat
4.    Laboratory monitoring of effectiveness at 6–8 weeks:3 
  (a) sUr  0.30 mmol/L, then continue allopurinol 
    (b) sUr  0.30–0.36 mmol/L, but no further attacks (without colchicine/NSAID/corticosteroids), then continue allopurinol 
    (c) sUr  0.30 mmol/L plus gout attacks/persistent tophi and uUr  1.5 mmol/24 hours, go to 5 
  (d) sUr  0.30 mmol/L plus gout attacks/persistent tophi with uUr  1.5 mmol/24 hours, go to 6
5.      Therapeutic advice: increase allopurinol (eg, +100 mg/day or double the dose); then go to 4. 
 Allopurinol inefficacy at maximum dosage (corrected for renal function): consider febuxostat
6.    Therapeutic advice: add uricosuricum, eg, benzbromarone 100 mg/day, or probenecid 500 twice daily; then go to 4
7.  Laboratory monitoring of effectiveness sUr and uUr (possibly pH4) after 6 months: see 5
8.  NB.: when trying to clear tophi, target value is sUr  0.30 mmol/L
Notes: 1Subject to motivation and tolerance by patient. 2Subject to calculated creatinine clearance (cCC)  50 mL/min, if cCC  50 mL/min, then only increase allopurinol 
with 100 mg/day. Serum oxipurinol concentrations might be measured in patients with renal insufficiency. 3Target value for sUr  0.36 mmol/L might be sufficient when there 
are no further gout attacks despite withdrawing colchicine/NSAID, otherwise lower target value of 0.30 mmol/L. 4If experiencing kidney stones or uUr  6.0 mmol/24 hours 
and pH  7.0 consider alkalising with sodium bicarbonate.
Abbreviations: sUr, serum urate; uUr, 24-hour excretion of urate in urine; NSAID, non-steroidal anti-inflammatory drug.
Table 1 Antihyperuricemic drugs in gout
Drug  Action: indication  Daily dose: standard  Distinct clinical 
pharmacological features
Allopurinol po XOi: all 100–900 mg: 300 mg Dosage adjustment to renal 
function
Benzbromarone po urate transporter: low excretor, subject 
to intolerance or allergy to allopurinol
50–200 mg: 100 mg Poor efficacy in severe renal 
function impairment
Febuxostat po XOi: all, particularly in allopurinol 
intolerance
80–120 mg: 80 mg No dosage adjustment in renal 
impairment
Probenecid po urate transporter: low excretor 500–2000 mg: 1000 mg Poor efficacy in moderate–severe 
renal function
Rasburicase iv UrO: lytic effect on tophi Compassionate use: eg, 0.2 mg/kg in 
60 min infusion on day 1, then 1 × per 
week; (+ methylprednisolone 100 mg iv)
Biological
Abbreviations: iv, intravenous; po, oral; UrO, urate oxidase; XOi, xanthine oxidase inhibitor.Clinical Interventions in Aging 2010:5 11
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patients 0.30 mmol/L may well be preferable; as has also 
been recommended by the British guidelines.35–38
There is some but not much evidence for these 
biochemical targets. But in practice they give clarity also to 
the patient. Another predefined aim of therapy particularly 
in elderly gout patients may be adhered to by clinicians 
treating elderly, ie, a normalization/any lowering of sUr to 
a level at which the gout patient does not need the chronic 
use of NSAIDs, glucocorticoids or colchicine; which was not 
specifically claimed for in aforementioned guidelines. Two 
main classes of drugs that reduce serum urate concentrations 
exist: xanthine oxidase inhibitors (XOi), such as allopurinol 
and febuxostat, and uricosuric drugs, such as benzbromarone 
and probenecid. XOi work by inhibiting uric acid production, 
thereby reducing serum urate concentrations. Uricosuric 
drugs inhibit the reabsorption of uric acid mediated by 
urate transporters. Rather few comparative randomized 
studies have been carried out comparing the effectiveness 
of these drugs.39–44
In the elderly, gout is often accompanied by renal function 
impairment and urate excretion is often low to very low. 
It must be kept in mind that when starting therapy with an 
XOi (uricostatics) it can take upto 8 weeks before a new 
steady state serum urate concentration is achieved. Secondly, 
when using allopurinol, the dosage should be tailored to renal 
function. However, since dosing tables for allopurinol are 
cautious and poorly investigated in clinically trials, these 
patients are often far from optimally treated.45–47 Possibly, 
febuxostat (in comparison to allopurinol) will provide a 
much more convenient and effective treatment option in this 
group of patients.
Special considerations when treating gout
Antihyperuricemic therapy might provoke arthritis or induce 
an attack of gout. For safety reasons, antihyperuricemic 
therapy should only be given after a gout attack has subsided, 
preferably with protection from colchicine, which should be 
initiated several days to 2 weeks earlier (0.5 mg twice daily).5,48 
With normal renal function, administration of allopurinol 
could be started at a dose of 100 mg once daily, probenecid 
250 mg twice daily and benzbromarone 100 mg once daily, 
and titrated every 2 weeks to standard dosage if tolerated. 
After 6 to 8 weeks, the efficacy can be evaluated and dose can 
be increased if necessary. Maintenance doses usually range 
from allopurinol 200 to 600 mg once daily, benzbromarone 
100 to 200 mg once daily and probenecid 500 to 1000 mg 
twice daily. In case of impaired renal function, allopurinol 
dosage should be started 100 or 50 mg/day (depending on 
renal function), evaluated after 6 to 8 weeks and titrated 
carefully (with 100 or 50 mg/day).
When frequent attacks of gout without joint damage or 
tophi are present in patients with intolerance or allergy to 
allopurinol and uricosurics, prophylaxis with colchicine at 
low doses can be prescribed, eg, 0.5 mg once or twice daily 
in patients with good renal function. In exceptional cases, 
corticosteroids, or a combination of a uricosuricum and 
allopurinol, may be indicated for maintenance therapy. When 
a history of urolithiasis is present, adequate diuresis should 
be ensured and alkalization should be considered, especially 
if a uricosuric is prescribed.
Compliance is also a special consideration when 
supervising gout patients, and it is crucial to explain the 
dosing schedule and any potential side effect to the patient 
in order to prevent early withdrawal.
Xanthine oxidase inhibitors
Position of XOi
Allopurinol, a purine-analogue, is widely prescribed as 
the daily urate-lowering treatment (ULT) of first choice. 
Allopurinol has been proven to be effective in all cases of 
hyperuricemia. Because of the long half-life of the active 
metabolite oxipurinol (14 to 28 hours), allopurinol can be 
administered once daily. It can be given as a single dose of 
commonly 300 mg daily and may be titrated up to a maximum 
800 mg daily if needed. In some patients only a daily dose 
of 100 mg may be adequate. Dosages above 300 mg/day are 
given 2 to 3 times daily.
By application of a dosage of 300 mg allopurinol the 
(British) target of sUr  0.30 mmol/L can be reached in 
20% to 26% of patients; but if tolerated, a dosage of 600 mg 
allopurinol is needed to reach aforementioned target in 
78% of patients as demonstrated recently in a prospective 
randomized controlled trial (RCT).43,44 Approximately 20% 
of patients using allopurinol report adverse events, with 5% 
discontinuing its use.49
Rare but life threatening is the allopurinol hypersensi-
tivity syndrome.50 Serious adverse reactions to allopurinol 
have been related to a decreased creatinine clearance rate 
and prolonged half-life of oxipurinol, and therefore it was 
proposed to adjust the allopurinol dose according to the 
rate of creatinine clearance.51 The dosage of allopurinol in 
individual patients should be tailored based on serum urate 
and calculated creatinine clearance.
Currently, an alternative XOi may be prescribed, ie, 
febuxostat.52,53 Up to now the predominant alternative treat-
ment option in cases of allopurinol intolerance has been a Clinical Interventions in Aging 2010:5 12
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uricosuric therapy. In one recent RCT benzbromarone 100 to 
200 mg daily showed similar success rates when compared 
with allopurinol 300 to 600 mg daily, and superior to the 
uricosuric probenecid.43,44 The long-term safety of benzbro-
marone however has not been a topic of research. As there 
was some doubt on its safety, it was withdrawn from the 
market in 2003.54,55
An emerging, potentially highly effective treatment is the 
use of uricase enzymes, such as rasburicase and pegloticase. 
In some individual cases and one clinical trial it is succes-
fully used to dissolve tophi.56,57
Febuxostat
Febuxostat pharmacology
The active substance is a new chemical entity designated as 
2-[3-cyano-4-(2-methlypropoxy) phenyl]-4-methlythiazole-
5-carboxylic acid (Figure 1). It is a non-purine, selective 
xanthine oxidase/xanthine dehydrogenase inhibitor. It is 
packed in a dosage of 80 or 120 mg febuxostat.
Febuxostat 10 to 120 mg/day dose-dependently reduced 
mean sUr levels from baseline by 25% to 70% in healthy 
volunteers; 24-hour urinary uric acid excretion at day 8 
was decreased by 46% to 66% relative to placebo.58 Both 
effects seemed to plateau at dosages 120 mg/day.58 Age 
(18 to 40 years versus 65 years) and sex had no clinically 
significant effect on the pharmacokinetic and pharmacody-
namic properties of oral febuxostat 80 mg/day in healthy 
volunteers.59
Absorption of febuxostat is rapid, with a time to Cmax 
of ≈1 hour. Febuxostat can be administered regardless of food 
or antacid intake.60 Pharmacokinetic values are linear in the 
range of 10 to 120 mg. Febuxostat is highly (98%) bound 
to human plasma proteins, mainly at the diazepam binding 
site. Elimination half-life of febuxostat is approximately 
12 hours. Febuxostat is mainly eliminated by glucuronidation 
in the liver. Also, some quantifiable active metabolites 67M-1, 
67M-2, and 67M-4 were found.61–63 No dosage adjustments 
are recommended in patients with mild to moderate renal 
impairment. Febuxostat inhibits cytochrome P450 isoen-
zyme 2D6, but interactions with CYP2D6 are not considered 
clinically significant. Just as in allopurinol, an important 
drug–drug interaction can occur with mercaptopurine and 
azathioprine due to inhibition of xanthine oxidase. Although 
no data are available yet, the combination of these drugs 
with febuxostat should be avoided.
Two phase I studies investigated the pharmacokinetics, 
pharmacodynamics, and safety of febuxostat in male and 
female subjects with normal or mild, moderate or severe renal 
function impairment.64,65 One study (n = 32) used febuxostat 
in the standard dosage of 80 mg/day.64 Although plasma 
exposure to febuxostat and its metabolites was generally 
higher in subjects with increasing degrees of renal impair-
ment, the percentages of decrease in serum uric acid were 
comparable regardless of the renal function group. A once-
daily 80-mg dose of febuxostat appears to be safe and well 
tolerated in different renal function groups and does not 
appear to require any dose adjustment based on differences 
in renal function.64
One open label phase I study (n = 27) investigated 
the pharmacokinetics and pharmacodynamics as well as 
safety of febuxostat in male and female subjects with 
normal liver function (n = 11) and subjects with mild 
(n = 8) and moderate (n = 8) hepatic impairment.66 Caveat: 
patients with severe hepatic impairment, according to 
Child–Pugh classification, were excluded, and febuxostat 
80 mg was given once daily for only 7 days. Overall, mild 
to moderate hepatic impairment did not significantly affect 
exposure to febuxostat or its active metabolites during this 
1-week period.
Clinical efficacy
In a phase II dose-response study the efficacy of 40 mg, 80 mg, 
and 120 mg/day febuxostat was evaluated in 153 patients with 
hyperuricemia (baseline sUr  0.48 mmol/L) and gout.67 
Patients were aged 23 up to 80 years. Subjects received 
febuxostat (40 mg, 80 mg, 120 mg) or placebo once daily 
for 28 days and colchicine prophylaxis for 14 days prior 
to and 14 days after randomization. Significantly more 
patients receiving febuxostat than placebo achieved an sUr 
level of 0.36 mmol/L) at each visit (P  0.001 for each 
comparison). The target sUr level (0.36 mmol/L) was 
achieved at study end in 0% of patients in the placebo group 
and 56%, 76% and 94% of patients in the 40 mg, 80 mg, and 
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Subjects who completed this study were entered into a 
5-year open-label extension study (FOCUS) and initially 
received febuxostat 80 mg daily.68 Between weeks 4 and 
24, dosing could be adjusted to febuxostat 40 or 120 mg. 
All subjects received gout flare prophylaxis during the first 
4 weeks. Gout flares were recorded and treated throughout 
the study, and sUr, baseline tophi and safety were monitored. 
Among 116 subjects initially enrolled, dose adjustments were 
made for 44 (38%) subjects. As a result, 8 subjects received 
febuxostat 40 mg, 79 received 80 mg, and 29 received 120 mg 
daily maintenance dose. At 5 years, 93% (54/58) of the 
remaining subjects had sUr  6.0 mg/dL (0.36 mmol/L). 
Fifty-eight subjects (50%) discontinued prematurely; 38 did 
so in the first year. The primary reasons for discontinuation 
were: personal reasons 22 (19.0%), adverse event 13 (11.2%), 
gout flare 8 (6.9%), lost to follow-up 5 (4.3%), protocol 
violation 1 (1%), other 9 (7.8%). Sustained reduction of 
sUr was associated with nearly complete elimination of gout 
flares. In 26 subjects with a tophus at baseline, resolution was 
achieved in 69% (18/26) by last visit on study drug at any 
point during the study. There were no deaths reported during 
the study. Long-term treatment with febuxostat resulted in 
durable maintenance of sUr  6.0 mg/dL for most subjects. 
There was nearly complete abolition of gout flares in patients 
completing the study. Baseline tophi resolved in a majority 
of subjects.68
In the phase III FACT trial, 762 patients with gout 
and with serum urate concentrations of at least 8.0 mg/dL 
(0.48 mmol/L) were randomly assigned to receive either 
febuxostat (80 mg or 120 mg) or allopurinol (300 mg) once 
daily for 52 weeks; 760 patients received the study drug.69 
Prophylaxis against gout flares with naproxen or colchicine 
was provided during weeks 1 through 8. The primary end-
point was a target sUr  6.0 mg/dL (0.36 mmol/L) at the 
last 3-monthly measurements. The secondary endpoints 
included reduction in the incidence of gout flares and in 
tophus area. The primary endpoint was reached in 47% 
to 59% of patients receiving 80 mg of febuxostat, 44% to 
74% of those receiving 120 mg of febuxostat, and 8% to 40% 
of those receiving 300 mg allopurinol (P  0.001 for 
comparison of each febuxostat group with the allopurinol 
group). The rates of discontinuation due to adverse events 
were higher in both the 80-mg febuxostat group and the 
120-mg febuxostat group than in the allopurinol group 
(Table 3). Categories and frequencies of treatment-related 
adverse events were not linked to discontinuation, but only 
published for all reported treatment-related adverse events.
Febuxostat was concluded, at a daily dose of 80 mg or 
120 mg, to be more effective than 300 mg allopurinol in 
lowering sUr.
Febuxostat reduced the median tophus area by 83% and 
66% in patients in the 80-mg and 120-mg groups compared 
with 50% in patients receiving allopurinol. Similar reduc-
tions in gout flares occurred in all treatment groups: 64% and 
70% in the 80-mg and 120-mg febuxostat groups, and 64% 










Mean decrease  
of serum urate 
sUr  6 mg/dl  
(0.36 mmol/L)  
final visit
sUr  5 mg/dL  
(0.30 mmol/L)  
final visit
Withdrawal   
due to ADR 
Becker67 Febuxostat 40 mg 37 28 days 37% 56% 21% –
Febuxostat 80 mg 40 44% 76% 49% –
Febuxostat 120 mg 38 59% 94% 88% –
Placebo 38 2% 0% 0% –
FACT69 Febuxostat 80 mg 257 52 weeks 45% 81% 47% 6.2%
Febuxostat 120 mg 251 52% 82% 66% 9.2%
Allopurinol 300 mg 254 33% 39% 13% 3.1%
APeX72 Febuxostat 80 mg 267 28 weeks 48% 72% – 6.7%
Febuxostat 120 mg 269 55% 79% – 5.9%
Febuxostat 240 mg 134 68% 92% – 8.2%
Allopurinol 300 mg 268 34% 39% – 6.7%
Placebo 134 4% 1% – 3.7%
CONFIRMS74 Febuxostat 40 mg 2269 in total 6 months – 45% – –
Febuxostat 80 mg – 67% – –
  Allopurinol 200/300 mg     – 42% – –Clinical Interventions in Aging 2010:5 14
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8-week period of prophylaxis against gout flares due to urate 
mobilization probably was too short, as many gout attacks 
were noticed in the first weeks afterwards in all groups. This 
might be one of the reasons that no differences in reduction 
of gout flares were seen. Another point of discussion is the 
dose limit of allopurinol of 300 mg/day in this study, which 
is often considered as the “safe” maximum dosage.70,71 It is 
known that dosages up to allopurinol 600 mg/day are more 
effective, and the licensed maximum dosage is 800 mg/day 
(or 900 mg/day in some countries).44
In the APEX trial, 1072 patients with gout, including 
persons with impaired renal function, and with sUr con-
centrations of at least 0.48 mmol/L were randomy assigned 
to receive either febuxostat (80 mg or 120 mg or 240 mg) 
versus allopurinol (300 mg or 100 mg) once daily for 
28 weeks versus placebo.72 Significantly higher percentages 
of subjects treated with febuxostat 80 mg (48%), 120 mg 
(65%), and 240 mg (69%) attained the primary endpoint of 
at least 3 monthly sUr levels 0.36 mmol/L compared with 
allopurinol (22%) and placebo (0%). A significantly higher 
percentage of patients with impaired renal function treated 
with febuxostat 80 mg (4 out of 9 = 44%), 120 mg (5 out 
of 11 = 45%), and 240 mg (3 out of 5 = 60%) achieved the 
primary endpoint compared with those treated with 100 mg 
allopurinol (0 out of 10 = 0%). Serious adverse events 
occurred similarly in all groups, although diarrhea and 
dizziness were more frequent in the 240 mg febuxostat group. 
Primary reasons for withdrawal were similar across groups 
except for gout flares, which occurred more frequent with 
febuxostat than with allopurinol. Schumacher et al concluded 
that at all doses studied febuxostat more effectively lowered 
and maintained serum urate levels 0.36 mmol/L than 
did allopurinol or placebo in subjects with hyperuricemia 
and gout, including in those with mild to moderate impaired 
renal function.72
Subjects who completed the FACT or APEX trial were 
invited to enroll in an open-label extension study and assigned 
to fixed-dose daily ULT with febuxostat (80 mg or 120 mg) 
or allopurinol (EXCEL).73 The majority of subjects were 
male, Caucasian, and in the age rabge of 45 to 65 years. 
ULT reassignment was permitted during months 1 to 6 to 
achieve sUr concentrations of 3.0 to 6.0 mg/dL (0.18 to 
0.36 mmol/L). Flares requiring treatment, tophus size, safety, 
and sUr levels were monitored during up to 40 months of 
ULT maintenance. After 1 month of initial treatment, 80% 
of subjects receiving either febuxostat dose, but only 46% 
of subjects receiving allopurinol, achieved sUr  6.0 mg/dL 
(0.36 mmol/L). After ULT reassignment, 80% of all 
remaining subjects maintained the primary efficacy endpoint 
of sUr  6.0 mg/dL at each visit. More subjects initially 
randomized to allopurinol required ULT reassignment to 
achieve sUr  6.0 mg/dL compared with subjects receiving 
febuxostat. Maintenance of sUr  6.0 mg/dL resulted in 
progressive reduction to nearly 0 in proportion of subjects 
requiring gout flare treatment. Baseline tophus resolution was 
achieved by 46%, 36%, and 29% of subjects maintained on 
febuxostat 80 mg, febuxostat 120 mg, and allopurinol, respec-
tively. Overall adverse event rates (including cardiovascular 
adverse event rates), adjusted for 10-fold greater febuxostat 
than allopurinol exposure, did not differ significantly among 
treatment groups. Durable maintenance of goal range sUr 
level with either dose of febuxostat or in smaller numbers 
of subjects with allopurinol resulted in near elimination of 
gout flares and improved tophus status over time.
In October 2008 the most recent clinical trial of febuxostat 
was presented at the Annual Meeting of the American College 
of Rheumatology.74 This 6-month phase III randomized, 
controlled, multicenter, double-blind trial comparing efficacy 
and safety of daily febuxostat and allopurinol in subjects with 
gout (CONFIRMS) trial randomized 2269 patients to receive 
febuxostat 40 mg/day, febuxostat 80 mg/day, or allopurinol 
200 or 300 mg/day depending on renal function (patients 
with glomerular filtration rate of 30 to 59 mL/min received 
200 mg/day of allopurinol). The primary endpoint was the 
proportion of patients achieving an sUr of less than 6 mg/dL 
(0.36 mmol/L) at the end of follow up. A secondary endpoint 
analyzed this same outcome in those patients with mild or 
moderate renal dysfunction defined as glomerular filtration 
rates of 60 to 89 and 30 to 59 mL/min, respectively. As in 
most of the previous febuxostat trials, a majority of the sub-
jects were middle-aged, (mean age 52.8 years) white males. 
Baseline sUr was 9.6 mg/dL and gout duration on average 
was 11.6 years; 1483 individuals had mild or moderate 
renal dysfunction. Urate lowering efficacy was similar with 
allopurinol 300 mg/day (42% achieved primary endpoint) 
and febuxostat 40 mg/day (45% achieved primary endpoint) 
but febuxostat 80 mg/day was statistically superior to the 
other two groups (67% achieved primary endpoint). Among 
patients with renal dysfunction, febuxostat 80 mg/day 
achieved the primary endpoint in a higher proportion of 
patients (72%) than in those taking febuxostat 40 mg/day 
(50%) or allopurinol (42%). Rates of adverse events were 
comparable across groups and at all levels of renal function. 
Specifically, no difference was reported in the rate of cardio-
vascular events (6 events were reported: 3 in the allopurinol 
arm and 3 in the febuxostat 80 mg/day group). Five deaths Clinical Interventions in Aging 2010:5 15
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occurred during the study, 1 in each febuxostat group 
and 3 in the allopurinol arm. CONFIRMS also provided 
additional evidence than that provided by the FACT and 
APEX trials supporting a stronger urate-lowering potency 
in the tested doses of febuxostat compared with allopurinol 
for those individuals with sUr greater than 10 mg/dL or 
with tophi.74,75
Efficacy and tolerability results of febuxostat in random-
ized controlled trials and long-term follow-up studies are 
summarized in Tables 3 and 4.
Febuxostat tolerability and safety
In terms of safety, to date, results from clinical trials have 
shown that febuxostat is well tolerated with a safety profile 
comparable to that of  placebo and allopurinol (Tables 3 
and 4). The most commonly reported adverse drug reactions 
(investigator assessment) are liver function abnormalities 
(3.5%), diarrhea (2.7%), headache (1.8%), nausea (1.7%), 
and rash (1.5%).76 In both the double-blind and extension 
phases, liver function test abnormalities were associated 
with colchicine administration.62 Diarrhea, nausea, and 
vomiting are more frequent in patients concomitantly treated 
with colchicine.76 Some serious rashes were reported with 
febuxostat in the APEX study.71 Since allopurinol can cause 
life-threathening cutaneous reactions (Stevens-Johnson 
syndrome) in rare cases, special attention to this serious 
adverse event is necessary.76
Some concerns about the safety of febuxostat have been 
expressed. Initial cardiovascular safety signals raised in the 
FACT trial and in the FDA clinical review of July 2006 have 
not been replicated in recently released phase III trial results. 
Postmarketing surveillance will be necessary to monitor 
rare but serious adverse events.
Febuxostat clinical utility 
in the elderly
Based upon currently available data and expert opinion, 
treatment with febuxostat should be considered indicated for 
patients with gout and associated hyperuricemia in several 
circumstances: allopurinol intolerance due to allergy or 
gastrointestinal complaints or biochemical side effects in 
blood counts or liver function tests. Currently, data are lacking 
about cross-allergy. Febuxostat may also be considered in 
mild to moderate renal impairment, ie, creatinine clearance 
20 to 60 mL/min, as well as in mild to moderate non-alcoholic 
hepatic impairment, ie, with ALAT  twice upper limit 
of normal.
Before prescribing febuxostat, one should check 
documentation of allopurinol intolerance/ineffectivity/
contraindication. Tests should be performed regarding full 
blood count, liver enzymes (ASAT, ALAT), albumen, thyroid 
function (TSH), renal function (creatinine), plasma uric 
acid and in 24-hour urine sample: uric acid and creatinine 
clearance. Prophylaxis should be given using colchicine 
in appropriate dosage or alternatively an NSAID at least 
3 days before starting febuxostat and prophylaxis should be 
continued until the target plasma uric acid has been reached 
(usually 3–6 months). When renal function is impaired 
(50 mL/min) febuxostat should be started at a lower dose: 
40 mg daily. During therapy, patients should be monitored 
according to national guidelines, eg, Table 5.
Conclusions
Reviewing the data, febuxostat can be regarded as a useful, 
novel, non-purine, selective and potent inhibitor of xanthine 
oxidase. Pharmacokinetics of febuxostat 10 to 120 mg daily 
are linear. No dose adjustment appears to be necessary in 
patients with mild-to-moderate renal impairment or mild-to-
moderate hepatic impairment. Febuxostat 10 to 120 mg daily 
rapidly and sustainably reduces serum uric acid by 25% to 
70%. Prophylaxis with colchicine or a NSAID is indicated 
preceding and during 6 months after initiating febuxostat. 
Febuxostat in clinical trials is well tolerated including 
those patients experiencing hypersensitity/intolerance to 
allopurinol.
Its antihyperuricemic efficacy at 80 to 120 mg/day is 
better than “standard dosage” allopurinol (300 mg/day). 
Febuxostat 80 mg daily appears to be equipotent to allopurinol 
450 mg/day or benzbromarone 100 mg/day. Long-term safety 
and efficacy data on tophus diminishment and reduction of 
Table 4 Efficacy and tolerability of febuxostat in long-term clinical follow-up
Study N Duration sUr  6 mg/dL  
(0.36 mmol/L)
Incidence of  





Withdrawal due   
to therapeutic  
failure
FOCUS68 116 5 years 93% 6% 69% –
eXCeL73 949 3 years 80% 4% 38%–44% 4.8%Clinical Interventions in Aging 2010:5 16
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gout flares have recently become available. Efficacy and 
tolerability of febuxostat compared to a uricosuric drug is 
to be determined in future studies.
Elderly onset gout has distinct clinical features in 
comparison to gout in middle-aged men, and co-medication 
and co-morbidity should be carefully evaluated. When 
preventive treatment is considered in this population, the 
potential benefits should outweigh the risks.
Antihyperuricemic treatment success strongly depends 
on strategic use of the available drugs. This includes sufficient 
prophylaxis of gout flares during start of antihyperuricemic 
treatment, choice of drug tailored to patient characteris-
tics, and dosage titration to target sUr levels. Febuxostat 
broadens the therapeutic options for antihyperuricemic in 
patients with gout. This is of clinical importance, especially 
for gout patients with currently unmet needs.
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